Leukaemia group backs Curis' dual Pi3K/HDAC inhibitor with $4 million
This article was originally published in Scrip
Executive Summary
Curis will be getting a boost of up to $4 million in funding from the Leukemia & Lymphoma Society (LLS), which has agreed to support 50% of the direct development costs for CUDC-907, a oral small molecule dual Pi3K and HDAC inhibitor under investigation as a treatment for patients with B-cell lymphoma and multiple myeloma.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.